1. Molecular genetics of adrenocortical tumor formation and potential pharmacologic targets.
- Author
-
Rauschecker M and Stratakis CA
- Subjects
- 3',5'-Cyclic-AMP Phosphodiesterases physiology, Adrenal Cortex Neoplasms drug therapy, Adrenocorticotropic Hormone physiology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Carcinoma drug therapy, Chromogranins, Cyclic AMP physiology, Cyclic AMP-Dependent Protein Kinases physiology, GTP-Binding Protein alpha Subunits, Gs deficiency, GTP-Binding Protein alpha Subunits, Gs genetics, GTP-Binding Protein alpha Subunits, Gs physiology, Humans, MicroRNAs physiology, Molecular Targeted Therapy, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins physiology, Receptors, Corticotropin deficiency, Receptors, Corticotropin physiology, Signal Transduction drug effects, Signal Transduction genetics, Wnt Proteins physiology, Adrenal Cortex Neoplasms genetics, Carcinoma genetics, Signal Transduction physiology
- Abstract
Abnormalities in the cAMP/PKA signaling pathway have been linked to the formation of benign adrenal tumors, as well as a possible predisposition to adrenocortical cancer. Mutations in the G-protein coupled receptor are associated with McCune-Albright syndrome and ACTH-independent macronodular adrenal hyperplasia, while defects in cAMP-dependent protein kinase A can lead to the development of Carney's complex, as well as primary pigmented nodular adrenocortical disease (PPNAD), and micronodular adrenocortical hyperplasia (MAH). Defects in phosphodiesterases, which regulate cAMP levels, have also been demonstrated in PPNAD and MAH. The Wnt signaling pathway, which is involved in oncogenesis in a variety of tumors, has also been implicated in adrenocortical tumorigenesis. MicroRNA profiling has added to our understanding of the signaling pathways involved in tumor formation in the adrenal cortex. Will this all lead to the development of specific targets for pharmacologic therapies? In this article, we review the molecular genetics of adrenocortical tumors and refer to potential targets for pharmacologic therapy.
- Published
- 2012